Humana Inc vs T-Mobile Us Inc — how do they compare? Humana Inc trades at $439.56 (market cap $47.61B), while T-Mobile Us Inc trades at $160.5 (market cap $179.83B). The key difference: T-Mobile Us Inc is far larger — about 3.8× Humana Inc's market cap, and T-Mobile Us Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and T-Mobile Us Inc for 84 Days on average.
| HUM | TMUS | |
|---|---|---|
Market Cap | $47.61B | $179.83B |
Volume | 1,827,332 | 3,882,740 |
Sector | Health | Media |
52-Week High | $409.85 | $230.06 |
52-Week Low | $163.67 | $161.73 |
Typical Hold Time | 53 Days | 84 Days |
Enterprise Value | $54.97B | $296.45B |
Dividend Yield | 0.89% | 2.79% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
T-Mobile US (TMUS) trades at $171.31, up 3.24% with recent earnings beats in Q1 and Q2 2026. The stock shows bearish technical signals but maintains strong fundamentals with $88.31B revenue, 11.45% net margin, and a 15% dividend increase announced September 2026. Analyst consensus remains strongly bullish with a $231.60 price target, though technical indicators suggest near-term resistance at $171.
TMUS presents a compelling growth story with improving profitability and strategic partnerships, but faces headwinds from rising debt levels and competitive pressures. The stock's current valuation at 17.54 P/E appears reasonable given earnings momentum, making it attractive for long-term investors despite technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →